Injectable calcium phosphate ceramics prevent osteoclastic differentiation and osteoporotic bone loss: Potential applications for regional osteolysis
Injectable calcium phosphate ceramics prevent osteoclastic differentiation and osteoporotic bone loss: Potential applications for regional osteolysis
复制标题
可注射磷酸钙陶瓷可防止破骨细胞分化和骨质疏松性骨丢失：局部骨溶解的潜在应用
DOI：
10.1016/j.msec.2020.110691
复制
发表时间：
2020-05-01
影响因子：
7.9
通讯作者：
Zheng, Li
中科院分区：
文献类型：
--
作者：
Heng, Shujun;Lu, Zhenhui;Zheng, Li
磷酸钙（CaPs）以块状形式存在，由于其体内吸收速度快，通常不适合骨质疏松症患者。然而，可注射的CaP粉末尚未研究其在骨质疏松宿主中的潜力。本文报道了纳米颗粒形式的cap可以抑制rankl刺激的破骨细胞分化（OC）和骨吸收，这可以通过抑制trap阳性细胞、f -肌动蛋白环分解和OC标志物表达下调来证明。CaP粉末还能显著抑制活化t细胞核因子κ B （nf - κ B）和核因子胞浆1 （NFATc1）的活化。此外，在脂多糖（LPS）诱导的小鼠模型中，可注射的cap逆转骨质流失，并在缺乏促成骨剂的情况下促进成骨细胞的形成。因此，注射用cap，特别是双相磷酸钙（BCP）可作为治疗炎症引起的骨溶解相关疾病的新药物。
Calcium phosphates (CaPs) in the form of blocks are typically not satisfied for administration to osteoporotic patients because of their rapid resorption rate in vivo. However, injectable CaP powders have not been investigated for their potential in osteoporotic hosts. Herein, CaPs in the form of nanoparticles was reported can inhibit RANKL-stimulated osteoclastic differentiation (OC) and bone resorption, as evidenced by suppressed TRAP-positive cells, disintegrated F-actin rings and downregulated expression of markers for OC. CaP powders also significantly inhibited nuclear factor-kappa B (NF-kappa B) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) activation. Furthermore, injectable CaPs reversed bone loss in a mouse model induced by lipopolysaccharide (LPS) and promoted osteoblastic formation in the absent of pro-osteogenic agents. Therefore, injectable CaPs, especially biphasic calcium phosphate (BCP), could be developed as novel agents for the therapy of osteolysis-related diseases caused by inflammation.